By Giulia Petroni

Novartis will submit an application next year for a possible accelerated approval of atrasentan in the U.S. after its phase 3 study met the primary endpoint.

The Swiss pharmaceutical company said Monday that the study showed a significant reduction in proteinuria, a condition causing high levels of protein in urine, in patients with kidney disease IgA nephropathy.

Novartis plans to review interim results with the U.S. Food and Drug Administration for a potential regulatory submission for accelerated approval. The study will continue, with final readout expected in the first quarter of 2026, it said.

Write to Giulia Petroni at giulia.petroni@wsj.com

(END) Dow Jones Newswires

October 30, 2023 02:52 ET (06:52 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024 Plus de graphiques de la Bourse Novartis
Novartis (NYSE:NVS)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024 Plus de graphiques de la Bourse Novartis